Sign in Subscribe
Genetic research

Researchers Identify Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma

Strategic Insights

— 1 min read

Scientists at the University of Nebraska Medical Center have made a groundbreaking discovery in the field of oncology, revealing new insights into the genetic drivers of angioimmunoblastic T-cell lymphoma (AITL). Using a comprehensive approach that combined whole-exome sequencing, transcriptomic analysis, and methylation analysis, the researchers identified several key mutations that contribute to the disease's progression and identified potential therapeutic targets.

Key Takeaways:

  • The study found that AITL, a subtype of T-cell lymphoma, has a dismal prognosis and is characterized by recurrent mutations in epigenetic drivers such as TET2, DNMT3A, and IDH2(R172).
  • The research identified novel mutations in TET3 and KMT2D, which were previously unknown to be associated with AITL.
  • Low expression of PHLPP2 mRNA predicted poor prognosis in AITL patients, highlighting the potential of PHLPP2 as a therapeutic target.
  • Engineered loss of PHLPP2 or TET2 in CD4(+) T-cells enhanced PI(3)K activation, indicating a potential therapeutic strategy for AITL.
  • The researchers demonstrated the effectiveness of PI(3)K inhibition as a treatment approach in AITL by utilizing a mouse model.
  • The study's findings have significant implications for the development of targeted therapies for AITL patients.

Statistics:

  • The study analyzed 124 whole-exome sequencing samples, 78 transcriptomic samples, and 40 methylation samples.
  • The research identified 11 recurrent mutations in known epigenetic drivers and 2 novel mutations.
  • Low PHLPP2 mRNA expression was observed in 30% of AITL patients.
  • Engineered loss of PHLPP2 or TET2 enhanced PI(3)K activation by 25%.
  • PI(3)K inhibition resulted in a 40% reduction in tumor growth in the mouse model.

Sources:

  • "Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities In Angioimmunoblastic T-cell Lymphoma." American Journal of Hematology, 2025.
  • University of Nebraska Medical Center, Dept. of Pathology Microbiology and Immunology, Omaha, NE 68198, United States.
  • National Institutes of Health (NIH) National Cancer Institute (NCI), NIH National Cancer Institute (NCI), Leukemia and Lymphoma Society, Research Council of Norway, SCOR grant from LLS.

Read more